Clinical effect of linezolid in pulmonary infection with methicillin resistant Staphylococcus aureus
10.3969/j.issn.1005-1678.2016.08.015
- VernacularTitle:利奈唑胺对甲氧西林耐药金黄色葡萄球菌肺部感染患者的临床疗效
- Author:
Fuquan QI
;
Hua YANG
- Publication Type:Journal Article
- Keywords:
linezolid;
MRSA;
pulmonary infection;
clinical effect
- From:
Chinese Journal of Biochemical Pharmaceutics
2016;36(8):65-67,70
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effect of linezolid in the treatment of pulmonary infection with methicillin resistant Staphylococcus aureus (MRSA).Methods 74 cases of pulmonary infection with MRSA were selected and randomly divided into control group and study group, 37 cases in each group.The control group received norvancomycin(1.0 g per time,twice daily) and the study group received linezolid (600 mg per time, twice daily) , with a consecutive treatment of 2 weeks.The inflammatory factors and related laboratory indicators were detected, the clinical efficacy, bacterial clearance rate and adverse reaction conditions were compared after the treatment.Results Compared with before treatment, serum levels of CRP, IL-1, IL-6 and TNF-αdecreased(P<0.05), levels of serum PCT, ET, NO and Lac decreased(P<0.05), compared with the control group, serum levels of CRP, IL-1, IL-6 and TNF-αin the study group were lower(P<0.05), levels of serum PCT, ET, NO and Lac were lower(P<0.05). There was no statistical difference in clinical efficacy rate between study group and control group (91.89% vs.81.08%), bacterial clearance rate of control group ( 70.27%) was lower than that the study group ( 89.19%) , and the difference was statistically significant ( P <0.05 ) . Conclusion Linezolid in the treatment of MRSA was effective with high safety, and it could reduce serum inflammation index.
